UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

Clinical cancer research, 2015-10, Vol.21 (19), p.4327-4336

2015

Volltextzugriff (PDF)

Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab

Nature communications, 2021-12, Vol.12 (1), p.7280-13, Article 7280

2021

Volltextzugriff (PDF)

Thoracoscopic Findings in IgG4-related Pleuritis

Internal Medicine, 2020/01/15, Vol.59(2), pp.257-260

2020

Volltextzugriff (PDF)

Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors

PloS one, 2023-09, Vol.18 (9), p.e0291772-e0291772

2023

Volltextzugriff (PDF)

The JRS Guidelines for the Management of Community-acquired Pneumonia in Adults:An Update and New Recommendations

Internal Medicine, 2006, Vol.45(7), pp.419-428

2006

Volltextzugriff (PDF)

Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a Dermatophagoides farinae-induced mouse model of chronic asthma

Allergology International, 2017-07, Vol.66 (3), p.432-439

2017

Volltextzugriff (PDF)

Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC

Journal of thoracic oncology, 2019-12, Vol.14 (12), p.2071-2083

2019

Volltextzugriff (PDF)

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)

Journal of thoracic oncology, 2015-01, Vol.10 (1), p.74-83

2015

Volltextzugriff (PDF)

Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors

Nagoya journal of medical science, 2021-11, Vol.83 (4), p.827-840

2021

Volltextzugriff (PDF)

Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012-08, Vol.18 (4), p.436-443

2012

Volltextzugriff (PDF)

Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis

Respirology (Carlton, Vic.), 2023-04, Vol.28 (4), p.380-388

2023

Volltextzugriff (PDF)

A recurrent case of eosinophilic pneumonia with high IL-25 levels

Allergology international, 2018-09, Vol.67, p.S38-S40

2018

Volltextzugriff (PDF)

Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay

Biomedicine & pharmacotherapy, 2022-11, Vol.155, p.113733, Article 113733

2022

Volltextzugriff (PDF)

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells

PloS one, 2015-10, Vol.10 (10), p.e0139809-e0139809

2015

Volltextzugriff (PDF)

Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis

Chest, 2008-05, Vol.133 (5), p.1196-1202

2008

Volltextzugriff (PDF)

Increased Levels of Plasma Galectin-9 in Patients with Influenza Virus Infection

The Tohoku Journal of Experimental Medicine, 2014, Vol.232(4), pp.263-267

2014

Volltextzugriff (PDF)

Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients

Oncoimmunology, 2014-11, Vol.3 (11), p.e970032-e970032

2014

Volltextzugriff (PDF)

Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2006-08, Vol.12 (4), p.195-202

2006

Volltextzugriff (PDF)

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

Lung cancer (Amsterdam, Netherlands), 2005-09, Vol.49 (3), p.337-343

2005

Volltextzugriff (PDF)

Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance

Cancer research (Chicago, Ill.), 2005-02, Vol.65 (4), p.1541-1546

2005

Volltextzugriff (PDF)

A case of necrotizing pneumonia caused by co-infection with influenza B and a Panton–Valentine leucocidin negative community acquired methicillin–resistant Staphylococcus aureus strain

The Japanese Journal of Antibiotics, 2018/04/25, Vol.71(2), pp.71-80

2018

Volltextzugriff (PDF)

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2010-09, Vol.5 (9), p.1404-1409

2010

Volltextzugriff (PDF)

Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4

Supportive care in cancer, 2016-02, Vol.24 (2), p.615-619

2016

Volltextzugriff (PDF)

Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer

Cancer treatment and research communications, 2024-01, Vol.40, p.100830, Article 100830

2024

Volltextzugriff (PDF)

Clinical Analysis of Patients with Pulmonary Nontuberculous Mycobacterial Disease Complicated by Pneumothorax

Internal Medicine, 2013, Vol.52(22), pp.2511-2515

2013

Volltextzugriff (PDF)

1 – 25 von 563

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(388)
Mit Volltextzugriff
(495)

Publikationsform

Sprache

Englisch
(450)
Japanisch
(131)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab

Thoracoscopic Findings in IgG4-related Pleuritis

Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors

The JRS Guidelines for the Management of Community-acquired Pneumonia in Adults:An Update and New Recommendations

Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a Dermatophagoides farinae-induced mouse model of chronic asthma

Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)

Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors

Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period

Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis

A recurrent case of eosinophilic pneumonia with high IL-25 levels

Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells

Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis

Increased Levels of Plasma Galectin-9 in Patients with Influenza Virus Infection

Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients

Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance

A case of necrotizing pneumonia caused by co-infection with influenza B and a Panton–Valentine leucocidin negative community acquired methicillin–resistant Staphylococcus aureus strain

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer

Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4

Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer

Clinical Analysis of Patients with Pulmonary Nontuberculous Mycobacterial Disease Complicated by Pneumothorax

Suchergebnisse filtern